Abstract 79P
Background
Neoantigens, a type of tumor-specific antigens derived from non-synonymous mutations, have become attractive targets for cancer immunotherapy. Approaches targeting private neoantigens derived from mutations that are unique to individual patients’ tumors are costly, labor-intensive and could lead treatment resistance due to antigen loss during clonal evolution. By contrast, vaccines targeting public neoantigens derived from recurrent mutations in cancer driver genes could be designed as “off-the-shelf” vaccines and would be broadly applicable to many cancer patients. However, this therapeutic approach relies on the accurate selection of highly recurrent mutations and identification of immunogenic neoantigens.
Methods
Here, we developed a pipeline with both computational prediction tools and experimental validation assays, known as NEX-NEO to expedite the identification of public neoantigens in 100 patients with colorectal cancer (n=50) and lung cancer (n=50). Furthermore, we developed a robust screening assay using K562 cells expressing HLA-A*11:01 as antigen presenting cells to validate their immunogenicity.
Results
By using NEX-NEO, we constructed an off-the-shelf neoantigen panel of 67 neoantigen candidates which cover 63% and 49% of colorectal and lung cancer patients, respectively. Of the 47 candidates for HLA-A1101 ligand, we identified 23 (48%) immunogenic peptides which are capable of activating CD8 T cells to produce IFN-γ and Granzyme B in PBMC from 10 healthy donors.
Conclusions
In conclusion, our study proposed a novel pipeline for the development of off-the-shelf neoantigen vaccines that could benefit a large proportion of cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Genetics Institute.
Funding
Nexcalibur Therapeutics.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract
101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Presenter: Kota Ouchi
Session: Poster Display
Resources:
Abstract